A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics.
Development of biotherapeutics is hampered by the inherent risk of immunogenicity, which requires extensive clinical assessment and possible re-engineering efforts for mitigation. The focus in the pre-clinical phase is to determine the likelihood of developing treatment-emergent anti-drug antibodies...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Public Library of Science (PLoS)
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/b3a2ef3195954b0488eb8607de448e39 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|